Results 151 to 160 of about 19,412 (203)

Collagenous endobronchial obliteration after chemoradiation followed by consolidation osimertinib: a case report. [PDF]

Front Oncol
Lee S, Choi J, Kim BH, Kim H, Lee SY.
europepmc   +1 more source

A systematic review and network meta-analysis of first-line EGFR-TKI-based combination strategies for EGFR-mutant non-small cell lung cancer with brain metastases. [PDF]

Sci Rep
Ma J, Zhao W, Guo W, Li Z, Lu X, Yang X, Jia C, Zhou Q, Jiang J.   +8 more
europepmc   +1 more source

Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging. [PDF]

Philos Trans R Soc Lond B Biol Sci
Eck MJ, Scott DA.
europepmc   +1 more source

Targeting Classical <i>EGFR</i> Mutations in Lung Cancer: Twenty Years of Progress and Beyond. [PDF]

Cancers (Basel)
Uehara Y, Hatano H, Zhang JT, Han J, Chua KLM, Saw SPL.   +5 more
europepmc   +1 more source

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial. [PDF]

Front Med (Lausanne)
Feng Q, Sun C, He J, Zhao Y, Sun C, Zhu H, Bi L.   +6 more
europepmc   +1 more source

Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review. [PDF]

Cancers (Basel)
Taing K, Lam HY, Hsu R.
europepmc   +1 more source

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study). [PDF]

Oncologist
Gariazzo E, Colamartini F, Cantale O, Mogavero A, Vitale A, Romano L, Peroni M, Rijavec E, Banini M, Mazzoni S, Montrone M, Pasello G, Veccia A, Ogliari FR, Leo S, Cortinovis D, Delmonte A, Belluomini L, La Cava G, Meoni G, Sini C, Delcuratolo MD, Bettini A, Pagano M, Genova C, Russo A, Pelizzari G, Tondulli L, Sergi C, Roca E, Bennati C, Grisanti S, Stanzione B, Mariotti S, Vavalà T, Soto Parra H, Ortega C, Pignataro D, Lacidogna G, Pino MS, Chiari R, Calabrò L, Pozzessere D, Masini S, Gelibter A, Scotti V, Grossi F, Tiseo M, Bria E, Metro G.   +49 more
europepmc   +1 more source

Osimertinib-induced cardiotoxicity is driven by HDAC-dependent epigenetic repression and rescued by vorinostat. [PDF]

Signal Transduct Target Ther
Toro Cora A, Bhati AS, Titus AS, Jaiswal A, Singh B, Umbarkar P, Li DY, Dutta R, Zhang Q, Verma SK, Tousif S, Lal H.   +11 more
europepmc   +1 more source

Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer. [PDF]

Thorac Cancer
Winardi W, Mitsuishi Y, Matsuda H, Takahashi F, Hayakawa D, Kanamori K, Nakamura I, Wirawan A, Hidayat M, Wibowo A, Shukuya T, Tajima K, Hayashi T, Kohsaka S, Takahashi K.   +14 more
europepmc   +1 more source

Molecular tumor board-guided osimertinib therapy in EGFR L858R/Q701L-mutant lung adenocarcinoma supported by functional validation. [PDF]

Oncologist
Albers-Leischner C, Ritgen M, Paulsen FO, Schmidt B, von Bubnoff N, Gorantla SP, Letsch A, Janning M, Loges S, Bokemeyer C, Christopeit M.   +10 more
europepmc   +1 more source